PharmaTimes January 11, 2024
The diagnostic system can deliver particles to the lungs via aerosol or a nebuliser
Engineers from the Massachusetts Institute of Technology (MIT) have designed a diagnostic system to make lung cancer screening more accessible globally.
The new technology could replace or supplement low-dose computed tomography (CT), the current gold standard for diagnosing lung cancer.
Based on nanosensors, sensors produce signals when detecting cancer-linked proteins in the lungs, which accumulate in the urine, where they can be detected with a simple paper test strip.
Researchers created two formulations of their particles: one that can be aerosolised and another delivered with a nebuliser, a dry powder delivered using an inhaler.
Consisting of polymer nanoparticles coated with a DNA barcode, particles are absorbed...
Today's Sponsors
Today's Sponsor